ClinConnect ClinConnect Logo
Search / Trial NCT05249543

Transdiagnostic Versus Diagnosis-specific Cognitive-behavioral Therapy

Launched by KAROLINSKA INSTITUTET · Feb 9, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Transdiagnostic Treatment Unified Protocol Cognitive Behavioral Therapy Anxiety Disorders Pilot Study

ClinConnect Summary

This clinical trial is studying two different types of cognitive-behavioral therapy (CBT) to see which is more effective for treating anxiety disorders, such as panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder. One type of therapy focuses on specific diagnoses, while the other is designed to address symptoms across different anxiety disorders. The goal of this pilot study is to determine if it is possible to conduct a larger trial and to see how well patients respond to each type of therapy in routine outpatient care in Stockholm, Sweden.

To participate in this study, individuals must be between 18 and 65 years old, able to speak Swedish, and have a main diagnosis of one of the specified anxiety disorders. They should also be on stable medication for at least six weeks before starting the treatment. Participants can expect to receive therapy tailored to their needs, and the study aims to ensure that they feel comfortable and supported throughout the process. It’s important to note that individuals with certain other mental health issues or severe risks, such as suicidal thoughts, cannot take part in the trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18-65 years of age,
  • Being able to speak Swedish without interpreter support,
  • A principal diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, or posttraumatic stress disorder, and
  • Pharmacological treatment (if any) that is stable six weeks prior to treatment start
  • Exclusion Criteria:
  • Current diagnosis of psychotic disorder, bipolar disorder, or moderate to severe substance use disorder,
  • Moderate to severe risk of suicide,
  • Psychiatric, somatic, or social problems which require other management or intervention than cognitive-behavioral therapy, and
  • Other simultaneous psychological treatment

About Karolinska Institutet

Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.

Locations

Stockholm, , Sweden

Patients applied

0 patients applied

Trial Officials

Benjamin Bohman, PhD

Principal Investigator

Karolinska Institutet

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials